☆ 4.7 Article

Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers

CANCER LETTERS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Gastroenterology & Hepatology

Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications

Miguel A. Martin-Serrano et al.

Summary: We present a comprehensive stratification of iCCA based on the tumor microenvironment (TME). The tumor is divided into five stable STIM classes, including 35% inflamed and 65% non-inflamed profiles. The inflamed classes, immune classical and inflammatory stroma, differ in oncogenic pathways and extent of desmoplasia. Analysis of cell-cell interactions highlights cancer-associated fibroblast subtypes as potential mediators of immune evasion. Among the non-inflamed classes, the desert-like class has the lowest immune infiltration with abundant regulatory T cells, while the hepatic stem-like class is enriched in 'M2-like' macrophages and specific mutations. Comparative analysis reveals high similarity between a KRAS/p19 murine model and the inflammatory stroma class. The KRAS-SOS inhibitor sensitizes a KRAS-mutant iCCA murine model to anti-PD1 therapy. Our findings provide valuable insights into the TME of iCCA and offer potential therapeutic targets for future research.

GUT (2023)

添加到收藏夹

Article Oncology

Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma

Liangqing Dong et al.

Summary: This study performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA) and revealed important features of iCCA pathogenesis. It identified subgroup-specific biomarkers and provided valuable insights into molecular pathogenesis and therapeutic opportunities in iCCA.

CANCER CELL (2022)

添加到收藏夹

Article Oncology

Immune Profiling of Combined Hepatocellular-Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy

Cong Trung Nguyen et al.

Summary: This study identified two immune subtypes of combined hepatocellular-cholangiocarcinoma (cHCC-CCA): an immune-high subtype characterized by higher densities of immune cells and activation of gene signatures related to immune response and immunotherapy in hepatocellular carcinoma (HCC), and an immune-low subtype. The immune-high subtype was associated with improved overall survival. These findings suggest that a subset of cHCC-CCA patients may benefit from immunomodulating therapeutic approaches.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial

Sophie Cousin et al.

Summary: Regorafenib combined with avelumab demonstrates antitumour activity in heavily pretreated biliary tract cancer patients, with a correlation to tumor microenvironment features.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Mucosal-associated invariant T-cell tumor infiltration predicts long-term survival in cholangiocarcinoma

Christine L. Zimmer et al.

Summary: The study found that MAIT cells were heterogenously lost from intrahepatic and perihilar cholangiocarcinoma tumors possibly in response to increased bacterial burden, while the residual intratumoral MAIT cells exhibited preserved receptor repertoire for interaction with tumor cells. The high presence of MAIT cells in the livers of iCCA patients predicted long-term survival and was associated with a favorable antitumor immune signature.

HEPATOLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?

Gonzalo Sapisochin et al.

Summary: Cholangiocarcinoma is the second-most common primary liver malignancy. Liver transplantation can be considered for intrahepatic and extrahepatic cholangiocarcinoma in select patients based on disease stage and patient characteristics.

HEPATOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1

Do-Youn Oh et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Clinical Safety and Efficacy of Locoregional Therapy Combined with Adoptive Transfer of Allogeneic γδ T Cells for Advanced Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Tingting Zhang et al.

Summary: The study aimed to assess the safety and efficacy of combining locoregional therapy with adoptive transfer of allogeneic gamma delta T cells for patients with HCC and ICC. The results showed that this novel combination treatment was safe and showed promising clinical efficacy against both types of cancer.

JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

High tumor mutation burden indicates a poor prognosis in patients with intrahepatic cholangiocarcinoma

Jian-Ping Song et al.

Summary: This study investigated the prognostic value of TMB in patients with ICC, and found that patients with high TMB had poorer overall survival and relapse-free survival compared to those with low TMB.

WORLD JOURNAL OF CLINICAL CASES (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

The immunogenomic landscape of resected intrahepatic cholangiocarcinoma

Fernando Carapeto et al.

Summary: This study integrated immunohistochemistry with next-generation sequencing to analyze intrahepatic CCA samples and found that T-cell and immune checkpoint markers were enriched at tumor margins compared to the center. High PD-1 or LAG-3 and low CD3/CD4/ICOS in the tumor center were associated with poor survival. Loss-of-function mutations in BRCA1-associated protein-1 were associated with elevated expression of the immunosuppressive checkpoint marker B7-H4.

HEPATOLOGY (2022)

添加到收藏夹

Correction Immunology

Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell-mediated antitumor activity

Hao Zheng et al.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing-Assisted Multiomics Analysis

Xuanwen Bao et al.

Summary: Through multiomics analysis, novel molecular subtypes of ICC were identified, and the chronic inflammation subtype was found to be associated with poor prognosis. The study also discovered KMT2D gene mutations associated with the metabolism subtype and APOE(+)C1QB(+) macrophage subtype associated with ICC prognosis.

CANCER IMMUNOLOGY RESEARCH (2022)

添加到收藏夹

Article Oncology

Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers

Wei Zhang et al.

Summary: The study found that NGS-guided targeted therapy and immunotherapy may offer better prognosis for patients with advanced or relapsed biliary tract cancer compared to traditional chemotherapy. The type of gene mutation in patients can guide the selection of appropriate treatment drugs, and TMB is a useful biomarker for predicting the efficacy of immunotherapy.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Article Oncology

PIWIL4 and SUPT5H combine to predict prognosis and immune landscape in intrahepatic cholangiocarcinoma

Wenbo Zou et al.

Summary: This study identified PIWIL4 and SUPT5H as pivotal biomarkers for predicting the prognosis of patients with intrahepatic cholangiocarcinoma. A prognostic signature was developed that effectively distinguished patients in high- and low-risk groups. The biomarkers were also found to be correlated with the tumor microenvironment, suggesting their potential value in prognostic prediction.

CANCER CELL INTERNATIONAL (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma

Laurence P. Diggs et al.

Summary: Stimulating antigen-presenting cells such as macrophages and dendritic cells through CD40 agonist significantly enhances the response to anti-PD-1 therapy in intrahepatic cholangiocarcinoma (iCCA) models, leading to a greater reduction in tumor burden. The combination of CD40 agonist and PD-1 inhibitor, along with chemotherapy, shows promising results in improving therapeutic efficacy and overall survival.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Oncology

Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy

Satyen H. Gohil et al.

Summary: Advances in single-cell analysis technologies have enabled the study of tumor heterogeneity, interactions between immune cells and tumor cells, and the evolutionary trajectory of each tumor. Multidimensional biomarker signatures will be crucial for guiding clinical decision-making for cancer patients.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Recent advances of immunotherapy for biliary tract cancer

Alessandro Rizzo et al.

Summary: Although immunotherapy has revolutionized the treatment landscape of several hematological and solid tumors, the role of ICIs and immune-based combinations in advanced BTC is still unclear. Despite ICI monotherapy has reported limited efficacy in this setting, the durable responses observed in sporadic cases suggest that testing patients for MMR, MSI, TMB, and PD-L1 expression is warranted. Results of currently ongoing trials are highly awaited.

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy

Corentin Louis et al.

Summary: Cholangiocarcinoma (CCA) is a rare and deadly cancer with limited effective treatments, leading to a need for new therapeutic strategies targeting the tumor microenvironment (TME). Single-cell RNA sequencing of the stroma in CCA provides a critical functional characterization of TME, paving the way for immunotherapies and other innovative treatments. Combining TME-targeted treatments with cytotoxic chemotherapy may yield better results, requiring the development of biomarkers to define patient populations for each strategy.

EXPERT OPINION ON THERAPEUTIC TARGETS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development

Xing Huang et al.

Summary: This study identified three potential tumor antigens associated with superior prognosis in cholangiocarcinoma and stratified cholangiocarcinoma patients into two immune subtypes based on molecular and clinical features. The findings provide a theoretical basis for the development of mRNA vaccines against cholangiocarcinoma and selection of suitable patients for vaccination.

MOLECULAR CANCER (2021)

添加到收藏夹

Review Oncology

Vaccine Therapies for Cancer: Then and Now

Michael A. Morse et al.

Summary: The development of therapeutic cancer vaccines faces challenges in clinical translation, but breakthroughs in cancer immunobiology and vaccine technologies offer hope for next-generation vaccine strategies to help cancer patients develop long-lasting anti-tumor immunity.

TARGETED ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase

Cristina Valero et al.

Summary: This study confirmed higher response rates for tumors with TMB of 10 or more mutations per megabase following immune checkpoint inhibitor therapy across multiple cancer types. However, the predictive value of a universal numerical threshold for high TMB was limited, indicating a need for further investigation.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Chimeric Antigen Receptor T Cells Targeting Integrin αvβ6 Expressed on Cholangiocarcinoma Cells

Nattaporn Phanthaphol et al.

Summary: CAR T cell therapy has shown efficacy in hematologic malignancies, but further investigation is needed for its application in solid tumors. The selection of target antigens highly expressed in cancer cells but not normal cells is crucial for successful immunotherapy.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes

Xiaofeng Chen et al.

Summary: This study found that KRAS and TP53 mutations are more frequent in advanced BTC, with KRAS-TP53 co-mutations associated with a favorable response to immunotherapy. Compared to GBC, CHOL has more mutations in genes involved in KRAS signaling, potentially leading to inferior immunotherapy outcomes. Additionally, a genomic signature including 11 genes was developed to predict prognosis and immunotherapy outcomes in CHOL and GBC.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

Anders Handrup Kverneland et al.

Summary: This study demonstrated high success rates of TIL expansion and tumor regressions in multiple solid cancer types when combining TIL ACT with CPIs. In vitro tumor reactivity was positively associated with treatment outcomes.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Oncology

Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology

Ashish Manne et al.

Summary: Recent advancements in precision medicine have made it possible to identify new molecular markers for BTCs, including epigenetic changes and non-DNA markers, providing hope for improved diagnosis and treatment outcomes.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Alternative Splicing-Based Differences Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Genes, Immune Microenvironment, and Survival Prognosis

Dingan Luo et al.

Summary: Alternative splicing events serve as novel biomarkers for tumor tumorigenesis and progression. In this study, differentially expressed alternative splicing events between hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) tissues and their normal tissues were identified, showing distinct immune features and clinical prognosis between the two types of cancer. This research provides valuable insights for the treatment of HCC and ICC.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma

Yu-Hua Huang et al.

Summary: The study investigated the clinicopathology, tumor immune microenvironment, and genomic landscape of Epstein-Barr virus (EBV)-associated intrahepatic cholangiocarcinoma (EBVaICC) in southern China, revealing unique characteristics and suggesting that patients with EBVaICC may benefit from immune checkpoint therapy.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Current and emerging therapies for advanced biliary tract cancers

Audrey E Kam et al.

Lancet Gastroenterology & Hepatology (2021)

添加到收藏夹

Article Oncology

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Angela Lamarca et al.

Summary: This study found that second-line FOLFOX chemotherapy can significantly improve overall survival in patients with advanced biliary tract cancer after progression on cisplatin and gemcitabine, indicating it should be considered as standard-of-care chemotherapy.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Construction of a competing endogenous RNA network related to the prognosis of cholangiocarcinoma and comprehensive analysis of the immunological correlation

Ning Wang et al.

Summary: This study identified a novel prognostic marker, SLC16A3, for CCA and revealed its regulatory role in the tumor microenvironment, providing new insights for the early diagnosis, prognosis, and targeted therapy of CCA.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma

Kamonlapat Supimon et al.

Summary: Current treatments for cholangiocarcinoma are largely ineffective due to late diagnosis, necessitating the development of improved therapeutic approaches. CAR T cell therapy shows promise as a potential treatment option, with MUC1 identified as a promising antigen for targeting. Further studies on anti-MUC1-CAR4 T cells demonstrate enhanced cytotoxic activity against CCA cells, supporting the potential of this approach as an adoptive T cell therapeutic strategy for cholangiocarcinoma.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Oncology

Lymphocyte to C-reactive protein ratio predicts long-term outcomes for patients with lower rectal cancer

Masaaki Nishi et al.

Summary: Post-CRT LCR is identified as a significant prognostic factor for overall survival in patients with lower rectal cancer, suggesting its potential as a prognostic biomarker for these patients.

WORLD JOURNAL OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?

Alice Boileve et al.

Summary: In the field of oncology, targeted and immune therapies have ushered in a new era over the last decade. While targeted agents are approved for hepatocellular carcinoma (HCC), immunotherapy is validated in combination with bevacizumab. Conversely, biliary tract cancer (BTC) is still investigational for immune therapies, with targeted therapies being crucial due to its complex molecular landscape. The review highlights the main prognostic and theragnostic biomarkers in HCC and BTC, as well as recommendations for clinical practice.

CANCERS (2021)

添加到收藏夹

Review Cell Biology

The State of Immunotherapy in Hepatobiliary Cancers

Farhan Z. Ilyas et al.

Summary: Hepatobiliary cancers, such as HCC, CCA, and GBC, have limited therapeutic options, but immunotherapy, including immune checkpoint inhibitors and adoptive cell transfer, has shown promise in improving outcomes for these challenging patients.

CELLS (2021)

添加到收藏夹

Article Oncology

Estimating tumor mutational burden across multiple cancer types using whole-exome sequencing

Chuang Zhou et al.

Summary: The study found that there may be differences in TMB threshold criteria among different cancer types, leading to variations in predicting the efficacy of ICI therapy. TMB was shown to predict clinical benefit in patients with colorectal cancer, but was not able to accurately predict outcomes in other cancer types.

ANNALS OF TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Oncology

A pan-cancer study of PD-1 and CTLA-4 as therapeutic targets

Zongqiang Cai et al.

Summary: The study found that PD-1 and CTLA-4 are highly expressed in certain malignancies, closely correlated with immune subtypes C2 and C6, and positively correlated with tumor microenvironment immune scores.

TRANSLATIONAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients

Yuki Kitano et al.

ANNALS OF SURGICAL ONCOLOGY (2020)

添加到收藏夹

Article Medical Laboratory Technology

The Cancer Immunotherapy Biomarker Testing Landscape

Eric E. Walk et al.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2020)

添加到收藏夹

Meeting Abstract Oncology

Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy

Claudia X. Dominguez et al.

CANCER DISCOVERY (2020)

添加到收藏夹

Review Oncology

Current standards and future perspectives in adjuvant treatment for biliary tract cancers

Angela Lamarca et al.

CANCER TREATMENT REVIEWS (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma

Sylvie Job et al.

HEPATOLOGY (2020)

添加到收藏夹

Article Oncology

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies

Sarina A. Piha-Paul et al.

INTERNATIONAL JOURNAL OF CANCER (2020)

添加到收藏夹

Review Immunology

Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research

Zhidong Wang et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Oncology

Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer

Yann Kieffer et al.

CANCER DISCOVERY (2020)

添加到收藏夹

Article Oncology

A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer

Richard D. Kim et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers A Systematic Review and Meta-analysis

Fausto Petrelli et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial

Oliver Klein et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma

Jianzhen Lin et al.

HEPATOBILIARY SURGERY AND NUTRITION (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma

Min Zhang et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma

Emilien Loeuillard et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

添加到收藏夹

Article Immunology

Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells

Thanich Sangsuwannukul et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2020)

添加到收藏夹

Article Immunology

Therapeutic vaccines for colorectal cancer: The progress and future prospect

Mina Shahnazari et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2020)

添加到收藏夹

Article Oncology

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

Leigh Marcus et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Meeting Abstract Oncology

Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).

Tatsuya Ioka et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma

Paola Bertuccio et al.

JOURNAL OF HEPATOLOGY (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

The tumour microenvironment and immune milieu of cholangiocarcinoma

Luca Fabris et al.

LIVER INTERNATIONAL (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Cholangiocarcinoma: Epidemiology and risk factors

Shahid A. Khan et al.

LIVER INTERNATIONAL (2019)

添加到收藏夹

Article Oncology

Allogenic V9V2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma

Mohammed Alnaggar et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Oncology

HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1

Chu-Yu Jing et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Meeting Abstract Oncology

Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.

Yung-Jue Bang et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

Pengfei Zhao et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules

Guoying Zhou et al.

JOURNAL OF HEPATOLOGY (2019)

添加到收藏夹

Article Oncology

MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers

Lirong Peng et al.

CANCER MEDICINE (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

Makoto Ueno et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)

添加到收藏夹

Article Oncology

Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma

Benjamin Goeppert et al.

BRITISH JOURNAL OF CANCER (2019)

添加到收藏夹

Review Oncology

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

Ferdinandos Skoulidis et al.

NATURE REVIEWS CANCER (2019)

添加到收藏夹

Article Oncology

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Julius Strauss et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

CAR T-cell Therapy: A New Era in Cancer Immunotherapy

Miliotou N. Androulla et al.

CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2018)

添加到收藏夹

Article Oncology

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study

Arndt Vogel et al.

EUROPEAN JOURNAL OF CANCER (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing

Xinyi Guo et al.

NATURE MEDICINE (2018)

添加到收藏夹

Review Biotechnology & Applied Microbiology

mRNA vaccines - a new era in vaccinology

Norbert Pardi et al.

NATURE REVIEWS DRUG DISCOVERY (2018)

添加到收藏夹

Article Oncology

Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers

Yelei Guo et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Review Oncology

Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma

Dan Hogdall et al.

TRENDS IN CANCER (2018)

添加到收藏夹

Article Oncology

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Zhong-Yi Dong et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Review Multidisciplinary Sciences

Elements of cancer immunity and the cancer-immune set point

Daniel S. Chen et al.

NATURE (2017)

添加到收藏夹

Editorial Material Medicine, General & Internal

First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication

Steven Lemery et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Cell Biology

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

Martina Schmittnaegel et al.

SCIENCE TRANSLATIONAL MEDICINE (2017)

添加到收藏夹

Article Cell Biology

Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation

Elizabeth Allen et al.

SCIENCE TRANSLATIONAL MEDICINE (2017)

添加到收藏夹

Article Oncology

Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma

Faiz Gani et al.

ANNALS OF SURGICAL ONCOLOGY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient

Markus W. Loeffler et al.

JOURNAL OF HEPATOLOGY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

Jesus M. Banales et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)

添加到收藏夹

Review Oncology

Classifying Cancers Based on T-cell Infiltration and PD-L1

Michele W. L. Teng et al.

CANCER RESEARCH (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Naiyer A. Rizvi et al.

SCIENCE (2015)

添加到收藏夹

Article Oncology

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody

Ross Stewart et al.

CANCER IMMUNOLOGY RESEARCH (2015)

添加到收藏夹

Article Medicine, Research & Experimental

Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer

Atsushi Aruga et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2014)

添加到收藏夹

Article Medicine, General & Internal

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Alexandra Snyder et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

添加到收藏夹

Article Multidisciplinary Sciences

Cancer Immunotherapy Based on Mutation-Specific CD4+T Cells in a Patient with Epithelial Cancer

Eric Tran et al.

SCIENCE (2014)

添加到收藏夹

Article Oncology

Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer

Atsushi Aruga et al.

CLINICAL CANCER RESEARCH (2013)

添加到收藏夹

Article Oncology

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

Douglas Hanahan et al.

CANCER CELL (2012)

添加到收藏夹

Article Gastroenterology & Hepatology

Immunization with aspartate-β-hydroxylase-loaded dendritic cells produces antitumor effects in a rat model of intrahepatic cholangiocarcinoma

Takehiro Noda et al.

HEPATOLOGY (2012)

添加到收藏夹

Article Gastroenterology & Hepatology

Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma

Koichi Shimizu et al.

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2012)

添加到收藏夹

Article Medicine, Research & Experimental

Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis

Munehiro Yoshitomi et al.

EXPERIMENTAL AND THERAPEUTIC MEDICINE (2012)

添加到收藏夹

Article Oncology

Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner

Neta Erez et al.

CANCER CELL (2010)

添加到收藏夹

Article Medicine, General & Internal

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.

Juan Valle et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.